Research programme: anti-interleukin-22 monoclonal antibodies - BioAtla/BioMotiv

Drug Profile

Research programme: anti-interleukin-22 monoclonal antibodies - BioAtla/BioMotiv

Alternative Names: anti-IL-22 monoclonal antibodies - BioAtla/BioMotiv; IL-22 antibodies - BioAlta/BioMotiv; Interleukin-22 antibodies - BioAtla/BioMotiv

Latest Information Update: 10 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioAtla
  • Developer BioMotiv
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin-22 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Inflammatory bowel diseases

Most Recent Events

  • 19 Feb 2014 BioMotiv acquires anti-IL-22 monoclonal antibodies from BioAtla
  • 19 Feb 2014 Early research in Cancer in USA (Parenteral)
  • 19 Feb 2014 Early research in Inflammatory bowel disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top